Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

The method for diagnosing sleep apnea includes measuring concentrations of biomarkers in a patient's bodily sample. To determine whether a patient suffers from sleep apnea, or has a predisposition for developing sleep apnea, a sample from the patient is analyzed. If one or more of the following biomarker concentrations are found in the patient's sample, then the patient may be diagnosed as suffering from sleep apnea or having a predisposition for developing sleep apnea: between approximately 992.8 pg/mL and approximately 1309.6 pg/mL of adipsin; between approximately 1,640 pg/mL and approximately 2,900 pg/mL of betatrophin; between approximately 8,090.82 pg/mL and approximately 11,829.07 pg/mL of brain-derived neurotrophic factor (BDNF); between approximately 11.82 pg/mL and approximately 88.26 pg/mL of interleukin-13 (IL-13); between approximately 49.45 pg/mL and approximately 103.29 pg/mL of tumor necrosis factor- (TNF-); and between approximately 16.55 pg/mL and approximately 29.76 pg/mL of the protein encoded by Human DNAJC27.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

The method for diagnosing sleep apnea includes measuring concentrations of biomarkers in a patient's bodily sample. To determine whether a patient suffers from sleep apnea, or has a predisposition for developing sleep apnea, a sample from the patient is analyzed. If one or more of the following biomarker concentrations are found in the patient's sample, then the patient may be diagnosed as suffering from sleep apnea or having a predisposition for developing sleep apnea: between approximately 992.8 pg/mL and approximately 1309.6 pg/mL of adipsin; between approximately 1,640 pg/mL and approximately 2,900 pg/mL of betatrophin; between approximately 8,090.82 pg/mL and approximately 11,829.07 pg/mL of brain-derived neurotrophic factor (BDNF); between approximately 11.82 pg/mL and approximately 88.26 pg/mL of interleukin-13 (IL-13); between approximately 49.45 pg/mL and approximately 103.29 pg/mL of tumor necrosis factor- (TNF-); and between approximately 16.55 pg/mL and approximately 29.76 pg/mL of the protein encoded by Human DNAJC27.

The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.